Skip to main content

Select Drug Profiles

Perspectives
A New Beginning
David B. Nash, MD, MBA
Read More
Practice Management
Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers
Rhonda Greenapple, MSPH
Stakeholder Perspective
Biologic Therapies for Rheumatoid Arthritis: It's All about Value
by Albert Tzeel, MD, MHSA, CPE, FAAPL
Read More
Practice Management
Impact of the Removal of the Monthly Liver Function Test Requirement for Ambrisentan
Louise A. Durst, RN, John Carlsen, MHA, Megan Kuchinski, MPH, Lauren Harner, JD, Daniel Neves, BA, Stephanie J. Harris, RN, BSN, Glenna L. Traiger, RN, MSN, CNS-BC
Stakeholder Perspective
The Challenges of Pulmonary Arterial Hypertension Management: Potential Benefits of Removing Monthly Testing
by James T. Kenney, RPh, MBA
Read More
First Cost Analysis of Long-Term Management of CML
Neil Canavan, Neil Canavan
Read More
Practice Management
Beyond the Cost of Biologics: Employer Survey Reveals Gap in Understanding Role of Specialty Pharmacy and Benefit Design
F. Randy Vogenberg, PhD, FASHP, Cheryl Larson, Margaret Rehayem, MA, Larry Boress, MPA
Stakeholder Perspective
An Educated Consumer Is Our Best Customer
by Atheer A. Kaddis, PharmD
Read More
Practice Management
Employers, Health Plans, and New Drug Benefit Designs: A Shifting Landscape
Mark Zitter, MBA, Michael Snyder
Read More
Graft-versus-Host Disease Often Leads to Posttransplant Readmission, High Costs
Read More
Is Plerixafor Cost-Effective for Stem-Cell Mobilization?
Caroline Helwick, Caroline Helwick
Read More
Leukemia, Oncology
Bosutinib Shows Superior Results in CML
Neil Canavan, Neil Canavan
Read More
Leukemia, Oncology
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
Caroline Helwick, Caroline Helwick, Caroline Helwick
Read More
Page 206 of 244
Results 2051 - 2060 of 2434